Concepts (94)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antihypertensive Agents | 6 | 2021 | 431 | 0.890 |
Why?
|
| Hypertension | 8 | 2021 | 1583 | 0.880 |
Why?
|
| Renin | 1 | 2012 | 98 | 0.400 |
Why?
|
| Community-Institutional Relations | 1 | 2010 | 42 | 0.350 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2011 | 142 | 0.350 |
Why?
|
| Leadership | 1 | 2010 | 265 | 0.290 |
Why?
|
| Ethical Review | 1 | 2004 | 6 | 0.230 |
Why?
|
| Societies, Medical | 1 | 2010 | 1318 | 0.230 |
Why?
|
| Ethics Committees, Research | 1 | 2004 | 41 | 0.230 |
Why?
|
| Research Subjects | 1 | 2004 | 64 | 0.220 |
Why?
|
| Blood Pressure | 5 | 2021 | 1558 | 0.210 |
Why?
|
| Fumarates | 2 | 2012 | 26 | 0.190 |
Why?
|
| Drug Recalls | 1 | 2020 | 4 | 0.180 |
Why?
|
| Amides | 2 | 2012 | 114 | 0.180 |
Why?
|
| Drug Contamination | 1 | 2020 | 51 | 0.180 |
Why?
|
| Drug Industry | 1 | 2020 | 88 | 0.180 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2020 | 60 | 0.170 |
Why?
|
| Drug Approval | 1 | 2020 | 174 | 0.160 |
Why?
|
| Carcinogens | 1 | 2020 | 391 | 0.160 |
Why?
|
| United States Food and Drug Administration | 1 | 2020 | 323 | 0.160 |
Why?
|
| Quality Control | 1 | 2020 | 460 | 0.160 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2022 | 394 | 0.160 |
Why?
|
| Drug Therapy, Combination | 4 | 2012 | 2325 | 0.150 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 2 | 2016 | 55 | 0.150 |
Why?
|
| Calcium Channel Blockers | 2 | 2022 | 143 | 0.140 |
Why?
|
| Atrial Fibrillation | 1 | 2022 | 726 | 0.120 |
Why?
|
| Renin-Angiotensin System | 2 | 2012 | 105 | 0.120 |
Why?
|
| White Matter | 1 | 2016 | 188 | 0.110 |
Why?
|
| Cerebrovascular Circulation | 1 | 2016 | 513 | 0.100 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2011 | 35 | 0.100 |
Why?
|
| Peripheral Arterial Disease | 1 | 2013 | 265 | 0.090 |
Why?
|
| Lipids | 1 | 2013 | 654 | 0.080 |
Why?
|
| Hydrochlorothiazide | 1 | 2009 | 72 | 0.080 |
Why?
|
| Tetrazoles | 1 | 2009 | 95 | 0.080 |
Why?
|
| Valine | 1 | 2009 | 180 | 0.080 |
Why?
|
| Heart Failure | 1 | 2022 | 2319 | 0.080 |
Why?
|
| Cardiovascular Diseases | 1 | 2021 | 2209 | 0.070 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2016 | 748 | 0.070 |
Why?
|
| Patient Education as Topic | 1 | 2010 | 744 | 0.060 |
Why?
|
| Scientific Misconduct | 1 | 2004 | 20 | 0.060 |
Why?
|
| Human Experimentation | 1 | 2004 | 51 | 0.060 |
Why?
|
| Lisinopril | 1 | 2002 | 29 | 0.050 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2010 | 1231 | 0.050 |
Why?
|
| Research Personnel | 1 | 2004 | 166 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2012 | 3841 | 0.050 |
Why?
|
| Humans | 12 | 2022 | 270014 | 0.050 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2002 | 177 | 0.050 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2002 | 242 | 0.040 |
Why?
|
| Body Height | 1 | 2021 | 234 | 0.040 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2022 | 316 | 0.040 |
Why?
|
| Stroke Volume | 1 | 2022 | 535 | 0.040 |
Why?
|
| Guideline Adherence | 1 | 2004 | 627 | 0.040 |
Why?
|
| Double-Blind Method | 3 | 2013 | 2585 | 0.040 |
Why?
|
| United States | 2 | 2020 | 15776 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2022 | 1808 | 0.030 |
Why?
|
| Systole | 1 | 2016 | 216 | 0.030 |
Why?
|
| Patient Safety | 1 | 2020 | 612 | 0.030 |
Why?
|
| Organ Size | 1 | 2016 | 689 | 0.030 |
Why?
|
| Niacin | 1 | 2013 | 58 | 0.030 |
Why?
|
| Azetidines | 1 | 2013 | 87 | 0.030 |
Why?
|
| Ezetimibe | 1 | 2013 | 97 | 0.030 |
Why?
|
| Simvastatin | 1 | 2013 | 99 | 0.030 |
Why?
|
| Femoral Artery | 1 | 2013 | 197 | 0.030 |
Why?
|
| Glomerular Filtration Rate | 1 | 2016 | 592 | 0.030 |
Why?
|
| Sulfonamides | 1 | 2002 | 1933 | 0.030 |
Why?
|
| Lipoproteins | 1 | 2013 | 229 | 0.030 |
Why?
|
| Cholesterol | 1 | 2013 | 658 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2011 | 33690 | 0.020 |
Why?
|
| Aged | 5 | 2016 | 73126 | 0.020 |
Why?
|
| Valsartan | 1 | 2009 | 26 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 2013 | 859 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2020 | 6752 | 0.020 |
Why?
|
| Male | 5 | 2016 | 127911 | 0.020 |
Why?
|
| Female | 5 | 2016 | 148480 | 0.010 |
Why?
|
| Risk Factors | 1 | 2020 | 17824 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2016 | 9463 | 0.010 |
Why?
|
| Time Factors | 1 | 2016 | 12952 | 0.010 |
Why?
|
| Adult | 3 | 2021 | 81690 | 0.010 |
Why?
|
| Celecoxib | 1 | 2002 | 198 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 15172 | 0.010 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2002 | 230 | 0.010 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2002 | 198 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2009 | 5062 | 0.010 |
Why?
|
| Cyclooxygenase 2 | 1 | 2002 | 494 | 0.010 |
Why?
|
| Isoenzymes | 1 | 2002 | 650 | 0.010 |
Why?
|
| Kinetics | 1 | 2002 | 2186 | 0.010 |
Why?
|
| Heart Rate | 1 | 2002 | 736 | 0.010 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2002 | 533 | 0.010 |
Why?
|
| Middle Aged | 3 | 2013 | 90027 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 7890 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2016 | 30923 | 0.010 |
Why?
|
| Pyrazoles | 1 | 2002 | 1539 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2002 | 2926 | 0.010 |
Why?
|
| Adolescent | 1 | 2002 | 32646 | 0.000 |
Why?
|